Observational study finds Shingrix linked to 12% lower risk of cardiovascular events — Evidence Review
Published in Nature Medicine, by researchers from University of Oxford, University of Bristol
Researched by
— the AI search engine for science
Table of Contents
The latest research suggests that the shingles vaccine Shingrix is linked to a modest reduction in heart attack and stroke risk among older adults, a finding that aligns with previous evidence connecting vaccination to cardiovascular benefits. Most related studies support this connection, indicating that vaccination against shingles and other infections may have broader protective effects on heart health, though more clinical trials are needed for confirmation. The original study can be found in the Nature Medicine journal.
- Several systematic reviews and cohort studies indicate that vaccines for influenza, pneumococcus, and herpes zoster can reduce cardiovascular event risks in older adults, supporting the new study’s findings of a cardiovascular benefit from Shingrix 1 2 6.
- Evidence from earlier research with live shingles vaccines and different populations also shows a reduction in stroke and cardiovascular events, although the magnitude and duration of protection may vary 1 3 5.
- While the new findings are promising, prior studies emphasize the need for randomized controlled trials to establish causation and to clarify mechanisms underlying these associations 1 2.
Study Overview and Key Findings
The potential link between infectious diseases and cardiovascular events has been a growing area of interest, given the high burden of heart disease and stroke among older adults. Shingles, caused by reactivation of the varicella-zoster virus, not only leads to significant morbidity but may also trigger inflammation and vascular complications. This new study is notable for its large-scale, real-world analysis and its focus on the newer recombinant shingles vaccine (Shingrix), which has largely replaced the older live-attenuated vaccine (Zostavax). The study’s approach—comparing cardiovascular outcomes before and after the adoption of Shingrix—provides important observational evidence, especially as randomized trials are still ongoing.
| Property | Value |
|---|---|
| Organization | University of Oxford, University of Bristol |
| Journal Name | Nature Medicine |
| Authors | Dr Maxime Taquet, Dr Hugo Pedder |
| Population | Adults aged 60 and over |
| Sample Size | 70,000 |
| Methods | Observational Study |
| Outcome | Cardiovascular events, including heart attacks and strokes |
| Results | Shingrix associated with a 12% lower risk of cardiovascular events |
Literature Review: Related Studies
To better understand how this study fits within the broader scientific context, we searched the Consensus paper database, which aggregates over 200 million research papers. The following search queries were used to identify relevant studies:
- shingles vaccine cardiovascular risk reduction
- Shingrix heart attack stroke prevention
- vaccination effects on cardiovascular events
Literature Review Table
| Topic | Key Findings |
|---|---|
| Does shingles vaccination reduce cardiovascular risk in older adults? | - Observational and cross-sectional studies suggest herpes zoster vaccination is associated with lower risks of stroke and cardiovascular events among older adults, with reductions ranging from 12% to 50% depending on age and vaccine type 1 3 5 6. |
| How do different types of shingles vaccines compare for heart protection? | - The newer Shingrix vaccine (recombinant, subunit) is associated with reduced cardiovascular events, but most previous studies focused on the older live-attenuated vaccine; direct comparative data are still limited 1 2 5. |
| What is the cardiovascular impact of other adult vaccines? | - Influenza and pneumococcal vaccines show consistent, significant reductions in cardiovascular events and mortality in older adults, with influenza vaccination reducing major cardiovascular events by up to 34% 1 7 8 9 11. |
| What mechanisms may link shingles or its vaccine to heart outcomes? | - Shingles infection increases the risk of cardiovascular events, especially stroke, possibly due to inflammation; preventing shingles via vaccination may lower this risk, and broader immunological effects are also hypothesized 2 4 6. |
Does shingles vaccination reduce cardiovascular risk in older adults?
Multiple studies have explored whether vaccination against herpes zoster can help prevent cardiovascular events. The new study’s finding of a 12% reduction in heart attacks, strokes, and related events among Shingrix recipients is consistent with previous observational research, which has demonstrated cardiovascular benefits from shingles vaccination in older adults.
- Systematic reviews and cross-sectional studies found that herpes zoster vaccination is associated with reduced stroke risk, with some studies reporting up to a 50% decrease in certain age groups 1 3.
- A cohort study in diabetic patients identified a significant reduction in major adverse cardiovascular events following herpes zoster vaccination 6.
- Observational studies using various designs (cohort, cross-sectional, self-controlled case series) consistently suggest a protective effect, though the degree of reduction and duration of protection can vary 1 3 5 6.
- The cardiovascular benefit appears to be most pronounced in the first few years after vaccination and may wane over time 3.
How do different types of shingles vaccines compare for heart protection?
The transition from the live-attenuated Zostavax to the recombinant Shingrix vaccine is an important context for interpreting new findings. Most earlier studies focused on Zostavax, while the current study adds evidence specifically for Shingrix.
- The recent observational study specifically links Shingrix to a 12% reduction in cardiovascular events, filling a gap noted in earlier reviews that lacked studies on the recombinant vaccine’s cardiovascular impact 1 2.
- Prior research on Zostavax showed a decrease in stroke risk, but comparative data between vaccine types are sparse 1 5.
- Safety data on both vaccines suggest they are generally safe for older adults, with no evidence of increased cardiovascular risk post-vaccination 5.
- Direct head-to-head comparisons of Zostavax and Shingrix regarding heart protection are still lacking, and randomized controlled trials would provide more definitive answers 1 2.
What is the cardiovascular impact of other adult vaccines?
Studies on vaccines for influenza and pneumococcus provide a broader context, illustrating that the cardiovascular benefits observed with herpes zoster vaccination are part of a wider trend.
- Systematic reviews and meta-analyses indicate that influenza and pneumococcal vaccination significantly reduce risks of cardiovascular events and mortality among older adults and those with chronic conditions 1 7 8 9 11.
- Influenza vaccination, in particular, is associated with a 34% lower risk of major adverse cardiovascular events, with even greater benefit for those with recent heart conditions 7 8 9.
- These findings have informed clinical guidelines, which now recommend influenza vaccination as part of secondary prevention in cardiovascular disease 8.
- The consistency of cardiovascular benefits across different vaccines supports the plausibility of the new findings for Shingrix 1 7 8 9 11.
What mechanisms may link shingles or its vaccine to heart outcomes?
The precise biological mechanisms underlying the link between shingles (or its prevention) and cardiovascular events remain an area of active research, but several plausible explanations have been suggested.
- Shingles infection has been shown to increase the risk of cardiovascular events, particularly stroke, potentially due to inflammatory effects on blood vessels 2 4 6.
- Observational studies report a spike in venous thromboembolic events following shingles infection, which could be mitigated by effective vaccination 2 4.
- Some researchers propose that more effective vaccines like Shingrix may reduce cardiovascular risk both by preventing shingles and by modulating immune response and inflammation 2 4.
- Ongoing trials are expected to clarify these mechanisms and determine whether the cardiovascular benefits of vaccination are direct or indirect 2 4 6.
Future Research Questions
While current evidence suggests a beneficial association between shingles vaccination and cardiovascular outcomes, there remain significant gaps and uncertainties. Further research is needed to establish causation, clarify mechanisms, and guide clinical recommendations.
| Research Question | Relevance |
|---|---|
| Does Shingrix vaccination reduce the incidence of cardiovascular events in randomized controlled trials? | Randomized evidence is needed to confirm observational findings and to rule out confounding factors, as current studies are primarily observational 1 2. |
| How does the duration of cardiovascular protection after Shingrix vaccination compare to other vaccines? | Understanding how long the protective effect lasts is crucial for vaccination policy, especially as prior studies suggest declining benefit over time 1 3. |
| Are certain populations (such as diabetics, immunocompromised, or ethnic groups) more or less likely to benefit from Shingrix? | Subgroup analyses may identify who benefits most, as some studies show variable effects by age, comorbidity, and ethnicity 2 3 6. |
| What are the biological mechanisms by which herpes zoster vaccination impacts cardiovascular risk? | Elucidating mechanisms will help clarify whether the benefit is due to reduced infection, immune modulation, or other factors, guiding vaccine development 2 4 6. |
| How does Shingrix interact with other vaccines and medications affecting cardiovascular risk? | Many older adults receive multiple vaccines and medications; understanding interactions can inform safe and effective preventive strategies 1 2 7 8. |